
1.1 Evolution of drug discovery approaches
1.2 Role and advantages of computational methods
1.3 Key concepts: ligands, receptors, targets, binding sites
1.4 Overview of in silico workflow in modern drug development
2.1 Chemical interactions: hydrogen bonds, hydrophobic forces, electrostatics
2.2 Receptor–ligand complementarity
2.3 ADME considerations in early design
2.4 Importance of three-dimensional structure
3.1 Primary to quaternary structure
3.2 Active sites, allosteric sites, and binding pockets
3.3 Protein structural databases (PDB, UniProt)
3.4 Structure preparation and cleaning for simulations
4.1 Chemical structure formats (SMILES, SDF, MOL2)
4.2 Tautomers, stereochemistry, and protonation states
4.3 Ligand libraries and compound databases (PubChem, ChEMBL, ZINC)
4.4 Ligand preprocessing and energy minimization
5.1 High-throughput virtual screening
5.2 Ligand-based vs. structure-based screening
5.3 Pharmacophore modeling and applications
5.4 Hit identification and prioritization
6.1 Rigid vs. flexible docking
6.2 Scoring functions: types and limitations
6.3 Docking algorithms: genetic algorithms, Monte Carlo, simulated annealing
6.4 Preparing receptor and ligand files for docking
7.1 AutoDock and AutoDock Vina workflows
7.2 Glide, GOLD, and MOE docking modules
7.3 Selecting grid parameters and docking settings
7.4 Evaluating docking accuracy (RMSD, scoring consistency)
8.1 Analyzing binding poses
8.2 Understanding interaction fingerprints
8.3 Visualizing results using PyMOL, Chimera, and Discovery Studio
8.4 Selecting top hits for further study
9.1 Introduction to MD simulations
9.2 Force fields (CHARMM, AMBER, GROMOS)
9.3 System setup, minimization, and equilibration
9.4 MD for refining docking results
10.1 Binding free energy concepts
10.2 MM-PBSA and MM-GBSA methods
10.3 Alchemical free energy methods
10.4 Assessing ligand–receptor stability and affinity
11.1 Physicochemical and pharmacokinetic descriptors
11.2 In silico toxicity models
11.3 Tools for ADMET prediction (SwissADME, pkCSM)
11.4 Integrating ADMET into computational workflows
12.1 Structure-based drug design for infectious diseases
12.2 Cancer target docking example
12.3 Lead optimization using computational tools
12.4 Translating in silico outcomes to experimental validation
Basics of Computational Drug Design and Molecular Docking is a comprehensive introductory course designed to provide learners with a strong foundation in modern in silico drug discovery approaches. As drug development increasingly relies on computational tools to reduce time, cost, and experimental failure, this course equips learners with the conceptual understanding needed to navigate structure-based drug design workflows with confidence.
The course begins by introducing the fundamental principles of molecular recognition, protein structure, and ligand chemistry, establishing the biological and chemical basis of drug–target interactions. Learners are guided through essential computational techniques such as virtual screening and molecular docking, with emphasis on understanding docking algorithms, scoring functions, and result interpretation rather than software-specific complexity. The course then advances into molecular dynamics simulations, where learners explore protein and ligand flexibility, system stability, and time-dependent behavior of biomolecular complexes.
Further modules focus on binding free energy calculations and ADMET prediction, helping learners understand how computational methods assess binding strength, drug-likeness, pharmacokinetics, and toxicity risks. Real-world case studies in infectious diseases and cancer drug discovery illustrate how these tools are applied in practical research and pharmaceutical pipelines. Throughout the course, emphasis is placed on integrating multiple computational techniques to support rational decision-making in drug discovery.
This course is designed for beginners and early-career learners from life sciences, biotechnology, pharmacy, chemistry, and related fields. By the end of the course, learners will have a clear, structured understanding of how computational drug design supports experimental research and contributes to the development of safer, more effective therapeutic candidates.